Treatment with the polyethylene glycol–conjugated FGF21 analog Pegbelfermin has also shown promising results in patients with MASH, namely a decrease in hepatic fat fraction and improvements in liver stiffness, biomarkers of liver damage, and fibrosis.16 Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.